A study about the feasibility of measuring EV-miRNA to monitor minimal residual disease (MRD) in AML patients showed that a set of miRNAs were enriched in circulating EVs and could be used to distinguish leukemia xenografts from healthy human CD34+ cells. Here, CD34 is linked to acute myeloid leukemia.